MARKET

VIR

VIR

VIR BIOTECHNOLOG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.00
-3.78
-15.24%
Opening 10:27 01/28 EST
OPEN
24.05
PREV CLOSE
24.78
HIGH
24.10
LOW
20.60
VOLUME
309.71K
TURNOVER
--
52 WEEK HIGH
27.48
52 WEEK LOW
11.65
MARKET CAP
2.30B
P/E (TTM)
-16.7317
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VIR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VIR News

  • The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
  • Benzinga.1h ago
  • Gilead Against Coronavirus, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article.7h ago
  • PLG, AIM, INO and ONCS among midday movers
  • Seeking Alpha - Article.21h ago
  • Vir Biotech up 21% on coronavirus buying frenzy
  • Seeking Alpha - Article.1d ago

More

Industry

Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+0.79%

Hot Stocks

Name
Price
%Change

About VIR

Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.
More

Webull offers Vir Biotechnology Inc (VIR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.